drugset / Trial / NCT00441896

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

NCT00441896

Phase 2 Completed 57 enrolled Marinus Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

The study consists of cohorts where participants are randomized, in a 2:1 ratio, to 1 of 2 sequences, A and B. In each cohort, Sequence A, comprised of participants, who will receive ascending doses of ganaxolone and ascending doses of placebo. Sequence B, comprised of participants, who will receive ascending doses of placebo and ascending doses of ganaxolone. The dosing level in each subsequent cohort will be based upon experience gained from previous cohorts.

Timeline

Start
2007-01
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule

Indications